Rexahn Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2001-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.rexahn.com
Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
- First Posted Date
- 2014-03-17
- Last Posted Date
- 2020-06-30
- Lead Sponsor
- Rexahn Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT02089334
- Locations
- 🇺🇸
Rexahn Site, Seattle, Washington, United States
RX-5902 Treatment of Subjects With Triple Negative Breast Cancer
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2020-01-06
- Lead Sponsor
- Rexahn Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02003092
- Locations
- 🇺🇸
Rexahn site, Arlington, Virginia, United States
🇺🇸Rexahn Site, Greenville, South Carolina, United States
Safety and Efficacy of RX-10100 to Treat Major Depressive Disorder
- First Posted Date
- 2011-01-10
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Rexahn Pharmaceuticals, Inc.
- Target Recruit Count
- 314
- Registration Number
- NCT01273376
- Locations
- 🇺🇸
Rexahn Investigative Site, Bellevue, Washington, United States
🇺🇸Rexahn Investigative Site (2), Bellevue, Washington, United States
🇺🇸Rexahn Investigative Sites, Lake Jackson, Texas, United States
A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer
Phase 2
Completed
- Conditions
- Metastatic Pancreatic Cancer
- Interventions
- Drug: RX-0201 plus Gemcitabine
- First Posted Date
- 2009-12-09
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- Rexahn Pharmaceuticals, Inc.
- Target Recruit Count
- 31
- Registration Number
- NCT01028495
- Locations
- 🇺🇸
Orchard Healthcare Research Inc., Skokie, Illinois, United States
🇺🇸Baptist Cancer Institute, Jacksonville, Florida, United States
🇺🇸Texas Oncology, P.A., McAllen, Texas, United States
Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Rexahn Pharmaceuticals, Inc.
- Target Recruit Count
- 118
- Registration Number
- NCT00839176
Efficacy Study of RX-10100 to Treat Erectile Dysfunction (ED)
Phase 2
Completed
- Conditions
- Erectile Dysfunction (ED)
- Interventions
- Drug: RX-10100 5mgDrug: PlaceboDrug: RX-10100 10mgDrug: RX-10100 15mg
- First Posted Date
- 2008-06-06
- Last Posted Date
- 2009-05-05
- Lead Sponsor
- Rexahn Pharmaceuticals, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00693056
© Copyright 2025. All Rights Reserved by MedPath